Table 2.
Demographic and clinical characteristics of treatment groups
| Characteristic | EX + TILS_vmPFC n = 29 | EX + SHAM_vmPFC n = 29 | TILS_dlPFC n = 26 | SHAM_dlPFC n = 28 |
|---|---|---|---|---|
| Age, mean (s.d.), y | 20.55 (5.35) | 19.76 (2.67) | 19.00 (1.13) | 22.57 (10.85) |
| Female sex | 24 (82.76) | 25 (86.21) | 23 (88.46) | 24 (85.71) |
| Self-reported race or ethnicity | ||||
| American Indian/Alaska Native | 0 | 0 | 1 (3.85) | 0 |
| Asian | 8 (27.59) | 6 (20.69) | 3 (11.54) | 7 (25.00) |
| Black/African American | 1 (3.45) | 1 (3.45) | 2 (7.69) | 2 (7.14) |
| White (not Hispanic or Latino) | 8 (27.59) | 14 (48.28) | 10 (38.46) | 9 (32.14) |
| Hispanic or Latino | 12 (41.38) | 8 (27.59) | 10 (38.46) | 10 (35.71) |
| Full time student | 22 (75.86) | 20 (68.97) | 22 (84.62) | 19 (67.86) |
| Employed | 7 (24.14) | 10 (34.48) | 9 (34.62) | 5 (17.86) |
| Fear domain and severity | ||||
| Bodily sensations | 8 (27.59) | 8 (27.59) | 7 (26.92) | 9 (32.14) |
| ASI-3 total, M (s.d.) | 57.25 (7.83) | 45.00 (14.95) | 54.29 (9.05) | 47.89 (11.07) |
| Closed spaces | 10 (34.48) | 9 (31.03) | 9 (34.62) | 8 (28.57) |
| CLQ total, M (s.d.) | 41.40 (14.78) | 34.00 (9.27) | 51.89 (9.45) | 39.88 (9.01) |
| Contamination | 5 (17.24) | 6 (20.69) | 5 (19.23) | 6 (21.43) |
| OCI-R, M (s.d.) | 41.00 (9.70) | 39.33 (9.29) | 28.60 (16.27) | 34.17 (14.47) |
| Public speaking | 6 (20.69) | 6 (20.69) | 5 (19.23) | 5 (17.86) |
| LSAS total, M (s.d.) | 94.67 (19.17) | 88.67 (25.44) | 71.40 (32.53) | 92.20 (17.05) |
| CEQ, treatment credibility, M (s.d.) | 4.87 (1.43) | 5.62 (1.61) | 4.21 (1.64) | 5.25 (1.64) |
| CEQ, treatment expectancy, M (s.d.) | 31.72 (16.92) | 37.59 (22.47) | 27.69 (19.25) | 44.64 (21.68) |
ASI-3, Anxiety Sensitivity Index 3; CLQ, Claustrophobia Questionnaire; OCI-R, Obsessive-Compulsive Inventory-Revised; LSAS, Liebowitz Social Anxiety Scale; CEQ, Credibility/Expectancy Questionnaire.